

AAGCER AMERICAN ASSOCIATION for Cancer Research' AMERICAN AMERICAN AMERICAN AMERICAN AMERICAN AMERICAN ASSOCIATION For Cancer Research' Description The labor of concer research Description The labor of concer research

October 11-15, 2023 | Boston, MA

Poster presentations (as of 9/14/23)

Poster Session C Saturday, October 14 | 12:30 pm-4:00 pm Level 2, Exhibit Hall D

C001: *Retrospective analysis of TROP2 expression in colorectal cancer (CRC) primary tumors and liver metastases (LM) and its correlation with clinical factors*. Robert W. Lentz, University of Colorado School of Medicine, Aurora, CO United States.

C002: Identification of biomarkers predictive of sensitivity to the CHK1/2 inhibitor ACR-368 using highresolution phosphoproteomics and development of an ACR-368-tailored patient responder identification 3-marker test, ACR-368 OncoSignature. Caroline M. Wigerup, Acrivon AB, Lund, Sweden.

C003: A Quantitative Mass Spectrometry Workflow for Highly Multiplexed Measurement of Immunomodulatory Proteins to Support Immunotherapy Clinical Trials. Ons Ousji, CellCarta, Montreal, QC Canada.

C004: *Liquid biopsy based on the lipid profiles in plasma-derived extracellular vesicles which can be utilized for breast cancer diagnosis.* Masahiro Kawashima, Kyoto University, Kyoto, Japan.

C005: *TP53 Wildtype Status Can Predict Sensitivity to XPO1 Inhibitors in Patient-Derived Cancer Models*. Marie Maloof, Karyopharm Therapeutics, Newton, MA United States.

C006: *BID upregulation associates with sensitivity to TTK inhibitors in tumor cell lines*. Miguel A. Molina-Vila, Laboratory of Oncology, Pangaea Oncology, Dexeus University Hospital, Barcelona, Spain.

C007: *Improved T-cell and B-cell receptor repertoire profiling and immunophenotyping for biomarker discovery*. Alex Chenchik, Cellecta, Inc., Mountain View, CA United States.

C008: *Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cancer.* Yan Zhang, Eisai Inc., Nutley, NJ United States.

C009: *Biomarker analyses for predicting the benefit from immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer*. Mitsuo Osuga, Wakayama Medical University, Wakayama, Japan.

C010: A Comprehensive Predictive Biomarker Analysis for MEK Inhibitors in Patient-derived Xenograft (PDX) Models. Yanghui Sheng, Crown Bioscience, Suzhou, China (Mainland).

C012: *Exploring thrombospondin-1 variant and splicing factors as potential diagnostic biomarkers and therapeutic targets in thyroid cancer*. Seung Joon Baek, Seoul National University, Seoul, Korea, Republic of.

C013: Clinical biomarkers based on PK/PD modeling to guide the development for a first-in-class, highly selective SMARCA2 (BRM) degrader, PRT3789. Neha Bhagwat, Prelude Therapeutics, Inc., Wilmington, DE United States.

C014: *Pan-cancer Analysis Portrays NVL as a Diagnostic and Prognostic Biomarker*. Mousumi Datta, Gurunanak Institute of Pharmaceutical Science and Technology, Kolkata, India.



AMAGER American Association for Cancer Research NIH AMANNAL AMARCHAR INSTITUTE

October 11-15, 2023 | Boston, MA

C015: *FGFR1* and *RB1* Genetic Alteration Impair Clinical Benefit of CDK4/6 inhibitors plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer. Jianxin Zhong, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China (Mainland).

C016: *Evaluating clinical biomarkers of FHD-286, a potent and selective inhibitor of BRG1/BRM, in metastatic uveal melanoma.* Jessica Wan, Foghorn Therapeutics, Cambridge, MA United States.

C017: *Exploiting tumor RNA-sequencing data for prediction of immune checkpoint inhibition response*. Pieter Mestdagh, CellCarta, Antwerp, Belgium.

C018: *Prognostic worth of Nrf2/BACH1/HO-1 signals in the development of breast cancer*. Precious Barnes, University of Cape Coast, Cape Coast, Ghana.

C019: Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (*RW*) patient (*pt*) population using the Foundation Medicine genomic database. David J. Kwiatkowski, Brigham and Women's Hospital, Boston, MA United States.

C020: First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumors. Alison M. Schram, Memorial Sloan Kettering Cancer Center, New York, NY United States.

C022: Phase 1 Study of BDTX-1535, an Oral 4th Generation Inhibitor, in Patients with Non-Small Cell Lung Cancer and Glioblastoma: Preliminary Dose Escalation Results. Alex Spira, NEXT Oncology Virginia, Fairfax, VA United States.

C024: *Trial in progress: Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors.* Shivaani Kummar, Oregon Health and Science University, Portland, OR United States.

C025: *Trial in progress: First-in-human study of BBT-207 in advanced non-small cell lung cancer harboring EGFR mutation after treatement with EGFR TKI*. NaEun Jeon, Bridge Biotherapeutics, Inc., Seongnam-si, Korea, Republic of.

C026: *Initial Safety, Pharmacokinetics, and Recommended Phase 2 Dose from RAMP 203: A Phase 1/2 Study of Avutometinib + Sotorasib in KRAS G12C Mutant Non-Small Cell Lung Cancer.* Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA United States.

C027: *RSO-021, a first-in-class covalent inhibitor of mitochondrial PRX3: From bench to bedside*. George N. Naumov, RS Oncology LLC, Cambridge, MA United States.

C028: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors. Benjamin Schlechter, Dana Farber Cancer Institute, Boston, MA United States.

C029: Phase Ib/II open label, multi-arm, parallel cohort dose finding and expansion study of NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors or docetaxel in patients with lung cancer (NuTide:303). Richard H. Wilson, Beatson West of Scotland Cancer Centre/University of Glasgow, Glasgow, United Kingdom.





October 11-15, 2023 | Boston, MA

C030: HARMONi-3: A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer. Jonathan Riess, University of California Davis Comprehensive Cancer Center, Sacramento, CA United States.

C031: A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI + bevacizumab compared to FOLFIRI + bevacizumab alone in second line metastatic colorectal cancer. Susanna Ulahannan, University of Oklahoma Health Sciences Center, Oklahoma City, OK United States.

C032: *NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study*. Sarah P. Blagden, Early Phase Clinical Trials Unit, Churchill Hospital, University of Oxford, Oxford, United Kingdom.

C033: *Preliminary pharmacodynamic evaluation of AU-007 in phase 1 dose escalation trial in patients with advanced solid tumors*. Timothy Wyant, Aulos Bioscience, Larkspur, CA United States.

C034: First in Human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors. Nadeem Q. Mirza, Aprea Therapeutics, Inc., Doylestown, PA United States.

C035: Chemotherapy plus HER2-targeted therapy versus endocrine therapy plus HER2-targeted therapy as first-line treatment in patients with HR+/HER2+advanced breast cancer: A real-world trial. Yuehua Liang, Peking University Cancer Hospital, Beijing, China (Mainland).

C036: A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer. Helena Yu, Memorial Sloan-Kettering Cancer Center, New York, NY United States.

C037: *Largescale organoid panel drug screening to short-track clinically-relevant output*. Mariusz Madej, Crown Bioscience, Leiden, Netherlands.

C038: *High throughput application of the NanoBiT Biochemical Assay for the discovery of selective p110α isoform binders that block its interaction with KRAS*. Mohamed (Soly) Soliman Ismail, The Francis Crick Institute, London, United Kingdom.

C039: *Discovery of a potent and orally bioavailable HPK1 degrader for the treatment of human tumors*. Dongzhou Liu, Global Drug Development Center, Huadong Medicine, Hangzhou, China (Mainland).

C040: *Discovery and Development of Novel ATG13 Degrading Compounds that Inhibit Autophagy and Treat Non-Small Cell Lung Cancer*. Patrick M. Hagan, Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA United States.

C041: Drug repurposing to target TGF- β in chemoresistant high-grade serous ovarian cancer. Michelle W.Y. Wong-Brown, University of Newcastle, Callaghan, Australia.

C042: Integrative analyses of CRISPR and drug screens identify a selective and potent compound for oral squamous cell carcinoma. Annie Wai Yeeng Chai, Cancer Research Malaysia, Subang Jaya, Malaysia.

C043: *Discovery of new drug combinations for metastatic colorectal cancer*. Eun-Jung In, WEHI, Parkville, VIC Australia.





October 11-15, 2023 | Boston, MA

C044: *Discovery and characterization of novel fragment binders of the VHR phosphatase as a drug target for cervix cancer*. Jiaqian Wu, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA United States.

C045: *Combinations of PI3K inhibitors with targeted oncology agents in multicellular spheroid models*. Thomas Dexheimer, Frederick National Laboratory for Cancer Research, Frederick, MD United States.

C046: *Rapid autopsy provides unique research opportunity to evaluate KRAS^{G12C} inhibitor resistance mechanisms in non-small cell lung cancer*. Hilal Ozakinci, Moffitt Cancer Center, Tampa, FL United States.

C047: Comprehensive curation of label-free proteomics data for 186 patient-derived xenograft (PDX) models in HuBase[™]. Hengyuan Liu, Crown Bioscience, Inc., Suzhou, China (Mainland).

C048: *Inducible activation of sgRNA libraries in tumor xenografts empowers large-scale in vivo target discovery screens*. Silvia Fenoglio, Tango Therapeutics, Boston, MA United States.

C049: Copenhagen Prospective Personalized Oncology (CoPPO) – The utility of using genomic profiling for tailored therapy in a Phase 1 setting. Laila Belcaid, Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

C050: Comprehensive analysis of causes for unsuccessful genomic profiling in a Phase 1 setting. Laila Belcaid, Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

C051: Alteration of protein translation by eIF4A1 inhibition exquisitely primes lymphoma cells to induction of ferroptosis. Paola Manara, University of Miami, Miami, FL United States.

C052: *Circumventing EGFR inhibitor resistance in NSCLC using transomics*. Christopher J. Nicholson, Pepper Bio, Cambridge, MA United States.

C053: *BACE1 cleaves EGFR to drive lung adenocarcinoma brain metastasis*. Shawn C. Chafe, McMaster University, Hamilton, ON Canada.

C054: *PARP16 modulates MYC expression and susceptibility of Ewing's Sarcoma cells to PARP1 inhibition*. Ou Deng, Moffitt Cancer Center, Tampa, FL United States.

C055: *Withaferin A offers novel targeted immunotherapy against high-grade serous ovarian carcinoma*. Jasmin C. Acosta, Rush University Medical Center, Chicago, IL United States.

C056: *Characterization of prostate cancer secretomes for therapeutic intervention*. Tarana Arman, Fred Hutchinson Cancer Center, Seattle, WA United States.

C057: *Fibrolamellar carcinoma single-nucleus RNA sequencing reveals alteration of mitochondrial energetic pathways*. Nihal Bharath, Boston Children's Hospital, Boston, MA United States.

C058: Clinical relevance of telomerase upregulation via TERT promoter mutation or TERC amplification in high-grade ovarian cancer. Felix Blanc-Durand, National University Singapore - Cancer Science Institute, Singapore, Singapore.

C059: *Probabilistic graph-based model uncovers druggable vulnerabilities in major solid cancers.* Stephanie T. Schmidt, The University of Texas MD Anderson Cancer Center, Houston, TX United States.



AACCR American Association for Cancer Research NHM ANDRAL ACACCR INSTITUTE

October 11-15, 2023 | Boston, MA

C061: *GNL3 promotes prostate cancer growth by regulating androgen receptor protein stability*. Edwin Cheung, University of Macau, Taipa, Macao (Greater China).

C062: *Discovery and clinical evaluation of a potent and selective* A_{2A/2B} *dual receptor antagonist*. Duane DeMong, Merck & Co. Inc., Boston, MA United States.

C063: OSE279, a PD-1 blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preclinical characterization and early clinical results of a First-In-Human (FIH) study in subjects with advanced malignancies. Philippe Cassier, Centre Léon Bérard, Lyon, France.

C064: Combination of D3L-002, an anti-TIGIT/PVRIG bispecific antibody, with D3S-001, a KRAS G12C inhibitor, transformed tumor microenvironment from "cold" to "hot" and achieved durable tumor remission in preclinical models. Tienan Wang, D3 Bio (Wuxi) Co. Ltd., Shanghai, China (Mainland).

C065: *Hematopoietic Progenitor Kinase 1 (HPK1) inhibition enhances antibody secretion, pro-inflammatory cytokine production and proliferation of primary human B cells*. David Ciccone, Nimbus Therapeutics, Boston, MA United States.

C066: *Update on the phase 1 trial of Nelmastobart in patients with advanced solid tumors*. Stephen S. Yoo, STCube, Inc, Seoul, Korea, Republic of.

C067: Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors. Goldy C. George, The University of Texas MD Anderson Cancer Center, Pearland, TX United States.

C068: *Factors associated with primary resistance to immune checkpoint blockade in early phase clinical trials*. François-Xavier Danlos, Gustave Roussy Institut, Villejuif, France.

C069: Toripalimab an anti-PD-1 antibody that demonstrates potent T cell activation and enhanced clinical efficacy irrespective of PD-L1 status. Xiaoguang Wang, Coherus Biosciences, Redwood, CA United States.

C071: *HBI-2375, a selective inhibitor of MLL1-WDR5 interaction, possesses desirable preclinical characteristics in solid tumors in combination with checkpoint inhibitors and also in leukemias in the future clinical investigations.* Farbod Shojaei, HUYABIO International, San Diego, CA United States.

C072: *Interpretation of patient-specific ex vivo immunotherapy response for ovarian cancer*. Willemijn Vader, VitroScan, Leiden, Netherlands.

C073: Single-cell spatial analysis reveals microenvironmental features that contribute to immune discrepancies between adult and pediatric nasopharyngeal carcinomas. Lanqi Gong, National Cancer Institute, Bethesda, MD United States.

C074: VPS34 inhibition delays activation-induced STING degradation to prolong STING signaling and improve anti-tumor efficacy in preclinical models. Madhumita Bogdan, Deciphera Pharmaceuticals, Waltham, MA United States.

C075: A first-in-class and highly selective SHP1 allosteric inhibitor exhibits robust anti-tumor immunity and synergizes with PD-1 blockade. Jun Gyu Kim, Research Institute, Dong-A ST Co., Ltd., Yongin-si, Korea, Republic of.





October 11-15, 2023 | Boston, MA

C076: *Evidence of TCR and BCR clonal dynamics with enitociclib monotherapy in patients with MYC+ non-Hodgkin lymphoma (NHL)*. Melanie M. Frigault, Vincerx Pharma, Inc., Palo Alto, CA United States.

C077: STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor *immunity and reshapes the tumor microenvironment*. Yaara Ofir-Rosenfeld, Storm Therapeutics Ltd, Cambridge, United Kingdom.

C078: *Pembrolizumab response in melanoma patients: An analysis of the tumor microenvironment*. Anna Juncker-Jensen, NeoGenomics Laboratories, Aliso Viejo, CA United States.

C079: Comprehensive immunophenotypic profiling sheds light on the dynamic interplay between immune cells in the 4T1 breast cancer model upon anti-PD1 and anti-CTLA4 immunotherapy. Martin Lange, NUVISAN ICB GmbH, Berlin, Germany.

C080: Ultra-high concentration nitric oxide (UNO) enhances anti-CTLA-4 treatment activity and induces a durable anti-tumor immune response. Yogev Sela, Beyond cancer, Rehovot, Israel.

C081: *Novel and selective inhibitors of KRAS*^{G12V}. Uday Kumar Surampudi, VRise Therpaeutics,Inc., Cambridge, MA United States.

C082: *SCD1 is a potent therapeutic target in MYC-amplified group 3 medulloblastoma*. Stefan Custers, McMaster University, Hamilton, ON Canada.

C083: HDAC6 inhibition increases proteasome activity and modulates the myeloma immunopeptidome to promote cytotoxic T-cell activity. James J. Driscoll, University Hospitals Cleveland, Cleveland, OH United States.

C084: *Metabolomic profiling identifies molecular modifiers contributing to proteasome inhibitor resistance in multiple myeloma*. Snehal M. Gaikwad, LCBG, CCR, NCI, NIH, Bethesda, MD United States.

C085: OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription, including MYC, in mCRPC. Bernice Matusow, Opna Bio, LLC, South San Francisco, CA United States.

C086: NP1867, a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2, functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples. Julian Blagg, NeoPhore Ltd, Cambridge, United Kingdom.

C087: *DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer*. Jennifer Castro, Accent Therapeutics, Lexington, MA United States.

C089: *PRMT5 as a novel druggable vulnerability for EWSR1-ATF1-driven clear cell sarcoma*. Bingbing X. Li, Oregon Health & Science University, Portland, OR United States.

C090: Novel combination of TRIP13 and Aurora kinase A inhibition demonstrated extensive DNA damage and immunogenic cell death in RB-deficient cancers. Soma Ghosh, M.D. Anderson Cancer Center, Houston, TX United States.

C091: *Liquiritigenin, an estrogen receptor beta agonist, enhances cholesterol biosynthesis inhibitor RO* 48-8071-induced growth inhibition of ovarian cancer cells. Salman Hyder, University of Missouri, Columbia, MO United States.



American Association for Cancer Research NINE INSTITUTE

October 11-15, 2023 | Boston, MA

C092: *PRMT1 promotes pancreatic cancer development and resistance to chemotherapy*. Bomin Ku, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea, Republic of.

C093: Unlocking the Potential of Metformin: Revealing its Impact on Colorectal Cancer Cells at a *Molecular Level*. Georges Nemer, Hamad bin Khalifa University, Doha, Qatar.

C094: *Blocking flotillin-1 palmitoylation abrogates TNBC tumor growth and metastasis*. Bryan McClellan, University of Texas at Austin, Austin, TX United States.

C095: The menin inhibitor VTP-50469 enhances the in vivo efficacy of established drugs against preclinical models of aggressive infant MLL-r acute lymphoblastic leukemia. Richard B. Lock, Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia.

C096: *Targeting the p53 pathway to treat pediatric Malignant Rhabdoid and Atypical Teratoid Rhabdoid Tumors.* Alaa Refaat, St Jude Children's Research Hospital, Memphis, TN United States.

C097: *Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma*. Sheila Singh, McMaster University, Hamilton, ON Canada.

C098: *Targeting high-expression LGR5 by an R-spondin-based peptibody-drug conjugate is efficacious against neuroblastoma*. Yukimatsu Toh, The Brown Foundation Institute of Molecular Medicine, Center for Translational Cancer Research, University of Texas Health Science Center at Houston, Houston, TX United States.

C099: *Establishment and characterization of an NUP98-KDM5A-driven AML XPDX model*. Armando Diaz III, XenoSTART, San Antonio, TX United States.

C100: *First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer*. Hirva Mamdani, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI United States.

C101: Preclinical and clinical pharmacokinetics (PK) of NBF-006, a novel siRNA inhibitor of glutathione-stransferase P (GSTP) encapsulated in a lipid nanoparticle (LNP), for treatment of advanced non-small cell lung cancer (NSCLC). Michael Hall, Nitto BioPharma, Inc., San Diego, CA United States.

C102: *mRNA-mediated restoration of BRCA-1 tumor suppressor function prevents tumor growth and reverses resistance to PARP inhibitors in triple-negative breast cancers*. Gilles Divita, DIVINCELL, NIMES, France.

C103: Preclinical and clinical safety and tolerability evaluation of NBF-006, a novel siRNA inhibitor of glutathione-s-transferase *P*(*GSTP*) encapsulated in a lipid nanoparticle (*LNP*) for treatment of advanced non-small cell lung cancer (*NSCLC*). Jian Liu, Nitto BioPharma, Inc., San Diego, CA United States.

C104: Targeted epigenomic inhibition of MYC enhances responses to immune checkpoint and EGFR inhibitors in preclinical models of NSCLC. Define Yarar, Omega Therapeutics, Cambridge, MA United States.

C105: A Systematic Evaluation of the Therapeutic Potential of Base Editing in Cancer Prevention and *Treatment*. Rona Merdler-Rabinowicz, Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD United States.





October 11-15, 2023 | Boston, MA

C106: *Identification of nucleic acid drug candidates against mesenchymal transition and its application to breast cancer and glioblastoma cells*. Kiyotsugu Yoshikawa, Doshisha Women's College of Liberal Arts, Kyotanabe, Kyoto, Japan.

C107: *INTASYL™ self-delivering RNAi therapeutic targeting BRD4 elicits on-target apoptosis of human tumor cells*. Andrew Boone, Phio Pharmaceuticals, Marlborough, MA United States.

C108: *Enhanced growth inhibition in lung cancer cells through NBF-006 combination therapy with chemotherapy or KRAS inhibitors*. Cima Cina, Nitto BioPharma, Inc., San Diego, CA United States.

C109: *INTASYL™ PH-894 self-delivering RNAi targeting BRD4 enhances the antigenicity of melanoma cells through MART-1 upregulation*. Brianna Rivest, Phio Pharmaceutical, Marlborough, MA United States.

C110: *miR195 - a potential therapeutic molecule for breast Cancer: Present and Future*. Neeru Saini, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.

C111: A Novel Human Monoclonal Antibody Targeting Active ADAM10 Demonstrates Anti-Tumor Effects in Colorectal Cancer. Prem Premsrirut, Mirimus Inc. and Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY United States.

C112: *L1CAM targeting antibody-based therapy as a novel approach for L1CAM positive lymphomas.* Giulio Sartori, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

C113: Discovery of a novel auristatin antibody drug conjugate drug linker with equal efficacy and reduced bone marrow toxicity compared to vedotin. Noah A. Bindman, Seagen, Bothell, WA United States.

C114: Dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). Jin-Ji Yang, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (Mainland).

C115: *Preclinical characterization of STRO-002, a clinical-stage anti-FolRα antibody-drug conjugate.* Robert Yuan, Sutro Biopharma, South San Francisco, CA United States.

C116: *Impact of human iPSC-derived MSC secretome in modulating radiation induced inflammation and brain vascular endothelial cell damage*. Kshama Gupta, Mayo Clinic, Jacksonville, FL United States.

C117: *Preclinical Characterization of Allogeneic CAR* γδ *T Cell Therapy for Prostate Cancer Targeting a Novel Dimeric Epitope on PSMA*. Nitya S. Ramadoss, Adicet Bio, Inc., Redwood City, CA United States.

C118: *Design of Programmable Peptide-Guided Oncoprotein Degraders via Generative Language Models*. Pranam Chatterjee, Duke University, Durham, NC United States.

C119: Combining forces: Integrating engineered bacterial therapeutics with targeted therapies for advanced-stage non-small cell lung cancer. Dhruba Deb, Columbia University, New York, NY United States.

C120: Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines. Hae Min Hwang, Cancer Research Institute, Seoul National University, Seoul, Korea, Republic of.





October 11-15, 2023 | Boston, MA

C121: *Development of CRB-701 (SYS6002): A novel site-specific, Nectin-4 targeting ADC*. Rachael Brake, Corbus Pharmaceuticals, Norwood, MA United States.

C122: The impact of the short-chain fatty acids on viability, motility and migration of oral squamous cell carcinoma cell line. Ariana S. Garcia, UPR Recinto de Mayagüez, San Juan, Puerto Rico.

C123: *Alloferon Inhibits Migration of Pancreatic Cancer by Regulating the Expression of IL-22Rα*. Hyejung Jo, Seoul National University College of Medicine, Seoul, Korea, Republic of.

C124: Assessment of the anticancer potential of a natural compound euphol in colorectal cancer from in vitro and in vivo mouse models. Ana Laura Vieira Alves, Barretos Cancer Hospital, Barretos, Brazil.

C125: *Development of attenuated orf virus as a new generation oncolytic viral vector*. Yumiko Yamada, Graduate Institute of Microbiology and Public Health, National Chung Hsing University, Taichung, Taiwan (Greater China).

C126: *Translational pharmacokinetic/pharmacodynamic (PK/PD) modeling of novel covalent Kelch-like ECH-associated protein 1 (KEAP1) activators.* Peter N. Morcos, Bayer, Whippany, NJ United States.

C127: *Discovery of AUR-112, a novel MALT1 protease inhibitor for the treatement of B cell lymphomas.* Dinesh Chikkanna, Aurigene oncology limited, Bangalore, India.

C128: *PT-112, a novel immunogenic cell death inducer, causes ribosomal biogenesis inhibition and organelle stress in cancer cells.* Christina Y. Yim, Promontory Therapeutics Inc., New York, NY United States.

C129: Development of new increased potency Ref-1/APE1 targeted inhibitors that show promise for clinical applications against solid tumors. Silpa Gampala, Department of Pediatrics and Herman B Wells Center for Pediatric Research, Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN United States.

C130: *Discovery and characterization of an MTA-cooperative and brain-penetrant PRMT5 inhibitor*. Haiyan Ying, Abbisko Therapeutics, Shanghai, China (Mainland).

C131: *Development of MTM24, a mithramycin analogue, as a targeted therapy for Ewing sarcoma.* Markos Leggas, St. Jude Children's Research Hospital, Memphis, TN United States.

C132: *SGN-35T: a novel CD30-directed antibody-drug conjugate for the treatment of lymphomas*. Kevin J Hamblett, Seagen, Inc., Bothell, WA United States.

C133: *BBT-4437, a novel, brain-penetrable, reversible pan-TEAD inhibitor targeting the Hippo signaling pathway in solid tumors.* Leila Revollo, Bridge Biotherapeutics, Inc., Newton, MA United States.

C134: *The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC)*. Varsha Ananthapadmanabhan, Dana-Farber Cancer Institute, Boston, MA United States.

C135: *Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers*. Didier Pez, Ryvu Therapeutics S.A, Krakow, Poland.

C136: VHL, PBRM1, and BAP1 mutation variants and response to first-line therapies in patients with *metastatic clear-cell renal cell carcinoma (mRCC)*. Jessica Zhu, University of Colorado Anschutz Medical Campus, Aurora, CO United States.



Antronak INFORMER INSTITUTE

October 11-15, 2023 | Boston, MA

C137: *Tumor-selective, chaperone-mediated targeting of ERK5 (MAPK7)*. Kevin P. Foley, Ranok Therapeutics, Waltham, MA United States.

C138: *The benefit of Ma recipe, A combination of Chinese herbal medicines for patients with advanced esophageal cancer: A retrospective case report series.* Jiangnan Feng, Tongrun Tang Traditional Chinese medicine clinic, Wuhan, China (Mainland).

C139: *The IRAK4 inhibitor emavusertib (CA-4948) synergizes with second generation BTK inhibitors acalabrutinib and zanubrutinib in MYD88-L265P mutated lymphoma cell lines.* Francesco Bertoni, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

C140: *BI 1810631 is a novel EGFR wild-type sparing, HER2-selective small molecule inhibitor that efficiently blocks HER2 mutant-driven lung cancer.* Martin Augsten, Boehringer Ingelheim RCV GmbH Co KG, Vienna, Austria.

C141: *Targeting SHP2-dependent adaptive resistance to BRAF and MEK inhibition in gliomas*. Abiola Abdulrahman Ayanlaja, Johns Hopkins University, Baltimore, MD United States.

C143: Unveiling Synergistic Interplay between KRAS^{G12C} Inhibitors and the Polyamine Synthesis Inhibitor SAM486 against lung cancer cells: An In Vitro Study. Rodrigo A. Lopez-Muñoz, Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia, Chile.

C144: *MEN1703/ SEL24, a potent PIM inhibitor, demonstrates promising anti-tumour activity in activated B cell like diffuse large B cell lymphoma, mantle cell lymphoma and marginal zone lymphoma cells.* Afua A. Mensah, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

C145: ANS014004, a novel small-molecule type II c-Met inhibitor effectively overcomes clinical-resistance MET mutations and exhibits antitumor activity in preclinical models of MET-amplified non-small cell lung cancer (NSCLC) and gastric cancer. Kevin Schaab, Avistone Biotechnology, Inc., San Diego, CA United States.

C146: VIC-1911, a selective Aurora kinase A inhibitor, synergizes with sacituzumab govitecan in triplenegative breast cancer. Jangsoon Lee, University of Hawai'i Cancer Center, Honolulu, HI United States.

C147: *The DNA replication checkpoint inhibitors, ATRN-1051 (WEE1i) and ATRN-119 (ATRi), are potentially well tolerated and effective cancer treatments.* Eric J. Brown, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA United States.

C148: *Type II ROS1 inhibitors and their liability on ROS1 rearranged non-small cell lung cancer with L2086F mutation*. Rajat Thawani, Oregon Health & Science University, Portland, OR United States.

C149: Efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK or ROS1 fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2. Stephen V. Liu, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC United States.

C150: *Targeted Inhibition of Homologous Recombination and Nonhomologous End Joining in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence*. Ivana Barravecchia, University of Michigan, Ann Arbor, MI United States.





October 11-15, 2023 | Boston, MA

C151: *BLU-451 is a CNS-penetrant, wild-type-sparing EGFR inhibitor with broad coverage of uncommon EGFR mutations across structure-based subsets.* Xiuning Le, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

C152: Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors: Preventing deleterious 'de-hinging' to improve tolerability. Timothy P.S. Perera, DeuterOncology NV, Liege, Belgium.

C153: *Rare BRAF mutations in menlanoma and beyond: Rationalizing the afficacy of B-raf inhibitors via HPC-based in silico/in vitro investigations.* Sabrina Pricl, University of Trieste, Trieste, Italy.

C154: *Investigation of indole-based molecules as a new class of TLK1 inhibitors in prostate cancer therapy*. Delna Johnson, Indian Institute of Technology, Gandhinagar, Gandhinagar, India.

C155: In-vitro Multicellular 3D-Spheroid Model Demonstrates the Synergistic Effect of 2-Domain Soluble FMS-Like Tyrosine Kinase-1 (2d-sFlt-1) for Breast Cancer Targeted Therapies. Adel Zaid I. Mutahar, Molecular Oncology Lab., Department of Studies in Biotechnology, University of Mysore, Mysore, India.

C156: Dasatinib targets an upregulated SRC family kinase gene in extramedullary leukemia, improving prognosis in these patients. Isabel Cunningham, Columbia University, New York, NY United States.

C157: *Targeting PIK3CA and CDKN2A alterations in Esophageal Adenocarcinoma with Alpelisib and Palbociclib*. Naryan Rustgi, Columbia University, New York, NY United States.

C158: *Predicting TKI responses in PDGFRA-mutant gastrointestinal stromal tumor*. Homma M. Khosroyani, Oregon Health and Science University, Portland, OR United States.

C159: ALK Signaling Primes the DNA Damage Response Allowing Exploitation of ATR inhibition in ALKdriven Neuroblastoma. Ruth H. Palmer, University of Gothenburg, Gothenburg, Sweden.

C160: *HMPL-653, a highly potent and selective CSF-1R inhibitor, targeting both tumor cells and tumor microenvironment.* Jia Hu, HUTCHMED Limited, Shanghai, China (Mainland).

C161: Identification of a reversible selective FGFR2 clinical development candidate with potency against gatekeeper and molecular brake mutations. John Fischer, Cogent Biosciences, Waltham, MA United States.

C162: Assessment of the potential for QTc prolongation by the investigational ATR inhibitor tuvusertib in patients with advanced solid tumors using integrated nonclinical and clinical assessments. Jatinder Kaur Mukker, EMD Serono, Billerica, MA United States.

C163: *KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition*. Elia Aguado-Fraile, Repare Therapeutics, Cambridge, MA United States.

C164: A phase 1 dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients with advanced solid tumors: an updated analysis. Neelesh Sharma, Prelude Therapeutics Incorporated, Wilmington, DE United States.

C165: Zurletrectinib, a next-generation TRK inhibitor shows strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation drugs. Paola Roa, University of Miami, Miami, FL United States.





October 11-15, 2023 | Boston, MA

C166: Development of BLX-3030, a Potent and Selective Inhibitor of CDK9 for the Treatment of N-MYC Driven NeuroEndocrine Prostate Cancers (NEPC). Hariprasad Vankayalapati, Biolexis Therapeutics, Inc., American Fork, UT United States.

C167: An SN38 dendrimer nanoparticle, DEP irinotecan (SN38-SPL9111), demonstrates efficacy in mouse models of gastrointestinal cancer and augments anti-tumor effects of immune checkpoint blockade and PARP inhibition. Jeremy R.A. Paull, Starpharma Pty Ltd, Melbourne, Australia.

C168: *Prognostic value of tumor microenvironment (TME) features in advanced, EGFR-mutant non-small cell lung cancer (NSCLC).* Lodovica Zullo, Institut Gustave Roussy, Villejuif, France.

C169: AVA3996, a novel pre|CISION™ medicine, targets a warhead to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage to elicit tumor cell kill. David Jones, Avacta Life Sciences, London, United Kingdom.

C170: *Understanding the role of metastatic-niche in metastatic progression*. Salwa Lin, University of Oxford, Oxford, United Kingdom.

C171: *Immune desert microenvironment is associated with poor outcome in Wilms tumors*. Xiaoping Su, UT MD Anderson Cancer Center, Houston, TX United States.

C172: *PTX3 blockade restores anti-tumor immunity through suppressing M2-like macrophages phenotypes in colon cancer*. Feng-Wei Chen, Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan (Greater China).

C173: Negative selection of ligand-receptor interactions mediating lymphocyte infiltration confers melanoma resistance to Immune Checkpoint Blockade therapy by turning hot tumors to cold. Sahil Sahni, National Cancer Institute, Bethesda, MD United States.

C174: *MerTK as a putative biomarker for treatment response in triple negative breast cancer*. Bridget E. Mehall, University of Wisconsin, Madison, WI United States.

C175: *The potential effect of KRAS inhibitors on tumor microenvironments*. Noritaka Tanaka, Kansai Medical University, Hirakata, Japan.